Over 100 years old and yet SNEF has never been so young and dynamic

[SNEFNEWS] August 2023

The first buildings are rising from the ground on the construction site of the Nantes CHU

Snef teams contemplate the future amphitheater in Building B at the new Nantes University Hospital Center.

It’s an impressive achievement that is taking shape over the months. During this phase, our teams’ work includes incorporating the electrical installations of this large-scale project, reflecting Snef's historical know-how.

[SNEFNEWS] July 2023

Groupe Snef supports research on pancreatic cancer screening

On Wednesday June 28, the Cap'Ten and Magellan networks held their plenary meeting at Groupe Snef headquarters in Marseille.

The Cap'Ten and Magellan networks were created by DIPDE (Division Ingénierie du Parc nucléaire et de l'Environnement/Nuclear Park and Environment Engineering Division) to strengthen ties between EDF and its partners, a network of industrial companies representing the French nuclear plant industry.

The objective is to develop links, share nuclear industry know-how and work together to ensure the success of the French nuclear park industrial program through concrete, pragmatic solutions.

This meeting was an opportunity for Antoine Vassallo, DIPDE’s Director to inaugurate the Snef Power Services’ virtual reality room in the presence of Isabelle Dreau, Groupe Snef’s Deputy Chief Executing Officer, Olivier Jouven, Groupe Snef’s Deputy Chief Executive Officer and David Klein, Snef Power Services’ Chief Executive Officer.

[SNEFNEWS] July 2023

Groupe Snef supports research on pancreatic cancer screening

As part of its CSR policy, Groupe Snef is making available to the Fondation Hôpital Saint Joseph a team of engineers and doctoral students from Snef Lab, its subsidiary. Working alongside Dr. Laquière, the Group is helping to advance a research project on pancreatic cancer screening, using artificial intelligence and deep learning technologies.

Early and accurate diagnosis of pancreatic cancer

It is estimated that there are around 9,000 new cases of pancreatic cancer in France each year. Pancreatic cancer is a disease that affects both men and women, and the vast majority of those diagnosed are over 50.

The prognosis after diagnosis is often pessimistic, with a low 20% 1-year survival rate. Recent studies estimate that pancreatic cancer could become the third most deadly cancer in Europe in the next few years.

Dr. Arthur Laquière's team, from the Hepato-Gastroenterology Department, wishes to develop molecular biology analyses (more precisely genetic analyses) of pancreatic cysts, particularly for patients over 70, in order to determine whether or not these cysts will develop into cancer, and to avoid unnecessary surgery. It is thanks to an early and accurate diagnosis that the chances of recovery will increase.

The aim of this research is to provide patients with a more reliable diagnostic test.

💬 « Our thanks to Groupe Snef for signing the Sponsorship Agreement to finance the IA EUS study on pancreatic cancer screening, promoted by Doctor Arthur Laquière and the research teams at Hôpital Saint Joseph.

With the invaluable support of our sponsors, we hope to advance research on pancreatic cancer screening by developing artificial intelligence and deep learning tools, in partnership with the CNRS and Groupe Snef» emphasize the teams at Saint Joseph Hospital Foundation in Marseille.